Impact of combined C1 esterase inhibitor/coagulation factor XIII. or n-acetylcysteine/tirilazad mesylate administration on leucocyte adherence and cytokine release in experimental endotoxaemia

Journal of International Medical Research

Volumn 36, Issue 4, 2008, Pages 748-759

  Birnbaum, Juergen ^a   Klotz, E ^a   Spies, C D ^a   Mueller, J ^a   Hein, O Vargas ^a   Feller, J ^a   Lehmann, C ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b DALHOUSIE UNIVERSITY   (Canada)

Author keywords

C1 esterase inhibitor; Coagulation factor XIII; Cytokines; Endotoxaemia; Intravital microscopy; N Acetylcysteine; Rats; Tirilazad mesylate

Indexed keywords

ACETYLCYSTEINE; BLOOD CLOTTING FACTOR 13 CONCENTRATE; COMPLEMENT COMPONENT C1S INHIBITOR; CYTOKINE; ENDOTOXIN; FLUIMUCIL ANTIDOT; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; TIRILAZAD; UNCLASSIFIED DRUG; ANTIOXIDANT; BLOOD CLOTTING FACTOR 13; PREGNANE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFICACY; DRUG MECHANISM; ENDOTHELIUM CELL; ENDOTOXEMIA; EXTRAVASATION; LEUKOCYTE ADHERENCE; MALE; NONHUMAN; PROTEIN BLOOD LEVEL; RAT; ANIMAL; BLOOD; CELL ADHESION; CYTOLOGY; DRUG COMBINATION; HUMAN; IMMUNOLOGY; LEUKOCYTE; METABOLISM; PHYSIOLOGY; RANDOMIZATION; VASCULAR ENDOTHELIUM; WISTAR RAT;

ACETYLCYSTEINE; ANIMALS; ANTIOXIDANTS; CELL ADHESION; COMPLEMENT C1 INHIBITOR PROTEIN; CYTOKINES; DRUG THERAPY, COMBINATION; ENDOTHELIUM, VASCULAR; ENDOTOXEMIA; FACTOR XIII; HUMANS; LEUKOCYTES; MALE; PREGNATRIENES; RANDOM ALLOCATION; RATS; RATS, WISTAR;

EID: 52049107378     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323000803600417     Document Type: Article

References (33)

1. Marti-Carvajal A, Salanti G, Cardona A: Human recombinant activated protein C for severe sepsis. Cochrane Database Syst Rev 2007; CD004388.
2. Liu D, Zhang D, Scafidi J, et al.: C1 inhibitor prevents Gram-negative bacterial lipopolysaccharide-induced vascular permeability. Blood 2005; 105: 2350-2355.
3. Croner RS, Lehmann TG, Fallsehr C, et al.: C1-inhibitor reduces hepatic leukocyte-endothelial interaction and the expression of VCAM-1 in LPS-induced sepsis in the rat. Microvasc Res 2004; 67: 182-191.
4. Lehmann C, Birnbaum J, Luhrs C, et al.: Effects of C1 esterase inhibitor administration on intestinal functional capillary density, leukocyte adherence and mesenteric plasma extravasation during experimental endotoxemia. Intensive Care Med 2004; 30: 309-314.
5. Zeerleder S, Caliezi C, van Mierlo G, et al.: Administration of C1 inhibitor reduces neutrophil activation in patients with sepsis. Clin Diagn Lab Immunol 2003; 10: 529-535.
6. Caliezi C, Zeerleder S, Redondo M, et al.: C1-inhibitor in patients with severe sepsis and septic shock: beneficial effect on renal dysfunction. Crit Care Med 2002; 30: 1722-1728.
7. Ueki S, Takagi J, Solto Y: Dual functions of transglutaminase in novel cell adhesion. J Cell Sci 1996; 109: 2727-2735.
8. Isobe T, Takahashi H, Ueki S, et al.: Activity-independent cell adhesion to tissue-type transglutaminase is mediated by alpha4beta1 integrin. Eur J Cell Biol 1999; 78: 876-883.
9. Noll T, Wozniak G, McCarson K, et al.: Effect of factor XIII on endothelial barrier function. J Exp Med 1999; 189: 1373-1382.
10. Wozniak G, Noll T, Akinturk H, et al.: Factor XIII prevents development of myocardial edema in children undergoing surgery for congenital heart disease. Ann NY Acad Sci 2001; 936: 617-620.
11. Crimi E, Sica V, Williams-Ignarro S, et al.: The role of oxidative stress in adult critical care. Free Radic Biol Med 2006; 40: 398-406.
12. Crimi E, Sica V, Slutsky AS, et al.: Role of oxidative stress in experimental sepsis and multisystem organ dysfunction. Free Radic Res 2006; 40: 665-672.
13. Atkinson MC: The use of N-acetylcysteine in intensive care. Crit Care Resusc 2002; 4: 21-27.
14. Del Sorbo L, Zhang H: Is there a place for N-acetylcysteine in the treatment of septic shock? Crit Care 2004; 8: 93-95.
15. Hein OV, Ohring R, Schilling A, et al.: N-Acetylcysteine decreases lactate signal intensities in liver tissue and improves liver function in septic shock patients, as shown by magnetic resonance spectroscopy: extended case report. Crit Care 2004; 8: R66-R71.
16. Spapen HD, Diltoer MW, Nguyen DN, et al.: Effects of N-acetylcysteine on microalbuminuria and organ failure in acute severe sepsis: results of a pilot study. Chest 2005; 127: 1413-1419.
17. Spies C, Giese C, Meier-Hellmann A, et al.: Influence of prophylactic administration of N-acetylcysteine on the clinical indicators of tissue oxygenation during hyperoxic ventilation in cardiac risk patients. Anaesthesist 1996; 45: 343-350 [in German].
18. Spies CD, Reinhart K, Witt I, et al: Influence of N-acetylcysteine on indirect indicators of tissue oxygenation in septic shock patients - results from a prospective, randomized, double-blind study. Crit Care Med 1994; 22: 1738-1746.
19. Eversole RR, Smith SL, Beuving LJ, et al: Protective effect of the 21-aminosteroid lipid peroxidation inhibitor tirilazad mesylate (U74006F) on hepatic endothelium in experimental hemorrhagic shock. Circ Shock 1993; 40: 125-131.
20. Liu P, Vonderfecht SL, McGuire GM, et al: The 21-aminosteroid tirilazad mesylate protect against endotoxin shock and acute liver failure in rats. J Pharmacol Exp Ther 1994; 271: 438-445.
21. Schmidt H, Schmidt W, Muller T, et al: Effect of the 21-aminosteroid tirilazad mesylate on leukocyte adhesion and macromolecular leakage during endotoxemia. Surgery 1997; 121: 328-334.
22. Semrad SD, Rose ML, Adams JL: Effect of tirilazad mesylate (U74006F) on eicosanoid and tumor necrosis factor generation in healthy and endotoxemic neonatal calves. Circ Shock 1993; 40: 235-242.
23. Zhang H, Spapen H, Manikis P, et al: Tirilazad mesylate (U-74006F) inhibits effects of endotoxin in dogs. Am J Physiol 1995; 268: H1847-H1855.
24. Birnbaum J, Hein OV, Luhrs C, et al: Effects of coagulation factor XIII on intestinal functional capillary density, leukocyte adherence and mesenteric plasma extravasation in experimental endotoxemia. Crit Care 2006; 10: R29.
25. Birnbaum J, Lehmann Ch, Klotz E, et al: Effects of N-acetylcysteine and tirilazad mesylate on intestinal functional capillary density, leukocyte adherence, mesenteric plasma extravasation and cytokine levels in experimental endotoxemia in rats. Clin Hemorheol Microcirc 2008; 39: 99-111.
26. Schmidt H, Schmidt W, Muller T, et al: N-Acetylcysteine attenuates endotoxin-induced leukocyte-endothelial cell adhesion and macromolecular leakage in vivo. Crit Care Med 1997; 25: 858-863.
27. Tassani P, Kunkel R, Richter JA, et al: Effect of C1-esterase inhibitor on capillary leak and inflammatory response syndrome during arterial switch operations in neonates. J Cardiothorac Vasc Anesth 2001; 15: 469-473.
28. Marin F, Corral J, Roldan V, et al: Factor XIII Val34Leu polymorphism modulates the prothrombotic and inflammatory state associated with atrial fibrillation. J Mol Cell Cardiol 2004; 37: 699-704.
29. Zhang XY, Hayasaka S, Hayasaka Y, et al: Effect of N-acetylcysteine on lipopolysaccharide-induced uveitis in rats. Jpn J Ophthalmol 2007; 51: 14-20.
30. Araki S, Dobashi K, Kubo K, et al: N-Acetylcysteine attenuates TNF-α induced changes in secretion of interleukin-6, plasminogen activator inhibitor-1 and adiponectin from 3T3-L1 adipocytes. Life Sci 2006; 79: 2405-2412.
31. Hsu BG, Lee RP, Yang FL, et al: Post-treatment with N-acetylcysteine ameliorates endotoxin shock-induced organ damage in conscious rats. Life Sci 2006; 79: 2010-2016.
32. Mumcu S, Alhan E, Turkyilmaz S, et al: Effects of N-acetylcysteine on acute necrotizing pancreatitis in rats. Eur Surg Res 2005; 37: 173-178.
33. Salahudeen A, Wang C, McDaniel O, et al: Antioxidant lazaroid U-74006F improves renal function and reduces the expression of cytokines, inducible nitric oxide synthase, and MHC antigens in a syngeneic renal transplant model. Partial support for the response-to-injury hypothesis. Transplantation 1996; 62: 1628-1633.